Indolent lymphoma-why not to sprint at the start of a marathon

被引：0
|
作者：
Doucet, Stephane [1 ,2 ]
Gordon, Leo I. [1 ,2 ]
机构：
[1] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 05期
关键词：
NON-HODGKIN-LYMPHOMA; RITUXIMAB MAINTENANCE; FOLLICULAR LYMPHOMA; BENDAMUSTINE; FLUDARABINE; PHASE-3; TRIAL;
D O I：
10.1038/nrclinonc.2013.53
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A new study has shown that rituximab and bendamustine provide better outcomes and less toxicity than rituximab plus CHOP chemotherapy in patients with indolent lymphomas. However, whether this represents a practice-changing development is unclear and we should not rush to judgement without answering some key questions.
引用
收藏
页码：251 / 252
页数：2
相关论文
共 50 条
12345